Multi-institutional study of Osimertinib dose-optimization in Non-small cell lung cancer patients with EGFR activating mutation aged 70 Years or older - Multi-institutional study of Osimertinib dose-optimization in Non-small cell lung cancer patients with EGFR activating mutation aged 70 Years or older(MONEY Trial)

Public Health Research Foundation0 个研究点目标入组 550 人开始时间: 2023年6月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1) Those with infection requiring systemic treatment. (2) Those with obvious interstitial pneumonia diagnosed by chest CT scan; a history of radiation pneumonitis or organizing radiation pneumonitis in the irradiated field is allowed. The presence or absence of interstitial pneumonitis shall be judged by the attending physician. (3) Those with concomitant or treated malignancy with possibility of recurrence within 2 years, which could affect assessment of the primary endpoint. (4) Those with psychiatric disorder or symptoms that affect daily life, thereby make participation in the study difficult. (5) Those with complications which are judged unsuitable for study participation, such as uncontrollable diabetes mellitus, uncontrollable hypertension, congestive heart failure, unstable angina pectoris, serious arrhythmia, severe cerebrovascular disease, etc. (6) Those with other complications or pre-existing medical conditions that would make participation in this study difficult, as judged by the attending physician.

发起方